Conclusion
In the coming years, making HEOR processes more accessible to patients will be increasingly important and it will be critical to take a multidisciplinary approach to achieving this. Incorporating patient perspectives into study designs will not only accelerate the full HEOR process, but it will lead to the generation of outcomes that are more meaningful to those living with disease. By targeting the moments that matter most to patients and caregivers, we will make new innovations more valuable to them and society as a whole. Aligning this evolution with the increasingly patient-centered focus within regulatory and HTA processes can only lead to more effective and accelerated decision-making. Co-creating and validating projects with patients will substantively change the patient’s status from object of inquiry to subject who understands how scientific research can increase their quality of life. Improving the way results are shared will ultimately render the entire process more open and accessible, furthering both its reach and its potential value to all. In turn, ensuring data is not just accessible but is understandable will further empower patients to become owners of their own health outcomes and improve shared decision-making with those supporting their care.
No one knows more about the patient’s experience than the patient does. It is time for stakeholders across the drug development and approval process to engage patients more deeply in every aspect of that process. Making HEOR more accessible is only the start. We are excited to be at the forefront of a new paradigm where HEOR is a two-way dialogue of empathy, partnership, understanding, and ultimately trust.
Thank you to all our contributors:
Gavin Jones Global Advisor, Rare Disease
Rosemary Jose Senior Director, Strategic Market Access
David Thompson CEO, Evidence & Access
Sophie Tsai Senior Scientist, Patient Centered Outcomes & Patient Engagement
Jasmine Malone Head of Patient Content
Lara Groves Principal Real-World Evidence Consultant
Oliver Childs Global Scientific Director
Priya Patel Principal Real-World Evidence Consultant
Larry Radican Vice President, HEOR
Karen Bailey Associate Director, Patient Centered Outcomes & Patient Engagement
Sonya Snedecor Executive Director, HEOR